Form 8-K - Current report:
SEC Accession No. 0001193125-25-125071
Filing Date
2025-05-22
Accepted
2025-05-22 16:16:19
Documents
16
Period of Report
2025-05-20
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d929611d8k.htm   iXBRL 8-K 28984
2 EX-1.1 d929611dex11.htm EX-1.1 328153
3 EX-99.1 d929611dex991.htm EX-99.1 17473
7 GRAPHIC g929611g0521002849068.jpg GRAPHIC 2393
8 GRAPHIC g929611g0521002850030.jpg GRAPHIC 2415
  Complete submission text file 0001193125-25-125071.txt   561642

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA teva-20250520.xsd EX-101.SCH 2878
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE teva-20250520_lab.xml EX-101.LAB 17168
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE teva-20250520_pre.xml EX-101.PRE 10807
19 EXTRACTED XBRL INSTANCE DOCUMENT d929611d8k_htm.xml XML 3614
Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16174 | Film No.: 25977366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)